| Name | Title | Contact Details |
|---|
IcareUSA Foundation is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Parker Health is a Mexican American founded company; a powerful global agent of change, driven by minority-led leadership, diversity, and innovation. Our mission is resolute: to advance healthcare and technology into the next century by simplifying complexities and realizing the potential of digital health innovation. At the core of our approach is the groundbreaking Parker EHR – a revolutionary Electronic Health Records Management System™ that redefines interoperability, accessibility, and compliance. This innovation empowers patients, healthcare providers, systems, governments, researchers, and payors through a seamless cloud-based architecture that harmonizes patient-centric data, diagnostics, outcomes, care protocols, practitioner engagement, and more. Headquartered in Washington, DC, Parker Health signifies a global catalyst for transformation, rewriting the rules of healthcare through innovative solutions that forge a brighter future.
Shape Up The Nation is the first corporate wellness company focused on leveraging the power of trusted social networks to promote healthy living.
Positron Corporation is a Fishers, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.